Jump to content

Introgen Wins European Patent Decision on p53 Gene

Recommended Posts

http://www.corporate-ir.net/ireye/ir_si ... _id=716612

AUSTIN, Texas, June 2 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN) announced today that it was successful in winning the decision regarding its opposition of European Patent 0 390 323 before the European Patent Office (EPO) in which all claims directed to therapeutic applications of the p53 gene, the active component of Introgen's ADVEXIN® molecular therapy, were finally revoked by the EPO's Technical Board of Appeals. The patent -- entitled Detection of Loss of the Wild-Type p53 Gene - - and licensed to Schering-Plough Corporation, was directed both to diagnosis of p53 gene mutations and to therapeutic applications of the p53 gene. In today's decision, all claims of the patent that purported to cover therapeutic applications of the p53 gene were finally revoked on the basis of insufficiency of the patent disclosure, affirming an earlier decision by the opposition division of the EPO. This is Introgen's third successful outcome over a period of years in oppositions involving European p53 gene patents controlled by or licensed to Schering-Plough.

Dr. David L. Parker, Introgen's vice president for Intellectual Property said, "This is a very important win for Introgen on the European patent front as this was the last of the three patents we had identified and targeted for revocation several years ago. In light of today's decision, we do not now see any patent impediment to commercialization of ADVEXIN therapy in Europe."

While some diagnostic applications of the p53 gene remain in dispute, the therapeutic claims of this patent can never be reintroduced, according to the EPO proceedings. Diagnostic applications of the p53 gene are not part of Introgen's commercialization plans. Treatments with Introgen's therapies are not dependent on p53 diagnosis.

Introgen has previously reported favorable results of oppositions against this European patent. An opposition is an administrative proceeding conducted by the European patent office for challenging the validity, and requesting patent revocation, of issued European patents.

To date, Introgen controls 29 issued patents and has a large number of pending patents in the United States and in commercially important foreign countries relating to its ADVEXIN therapy. In addition some patents address adenoviral p53 compositions, production, purification and use in the treatment of cancer. Importantly, some of Introgen's patents that are directed to adenoviral processing, purification and formulation are not limited in scope to Ad-p53 and cover generally commercial scale production and formulation of any adenovirus product.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using non-integrating tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates a multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.